Nazione: Israele
Lingua: inglese
Fonte: Ministry of Health
TELOTRISTAT ETHYL AS ETIPRATE
MEDISON PHARMA LTD
FILM COATED TABLETS
TELOTRISTAT ETHYL AS ETIPRATE 250 MG
PER OS
Required
IPSEN PHARMA, FRANCE
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
2019-03-18
Page 1 of 6 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only XERMELO 250 MG FILM-COATED TABLETS EACH FILM-COATED TABLET CONTAINS: TELOTRISTAT ETHYL (AS ETIPRATE) 250 MG Inactive ingredients and allergens in this medicine - see section 6 ‘ADDITIONAL INFORMATION’. See also ‘IMPORTANT INFORMATION ABOUT SOME OF THIS MEDICINE’S INGREDIENTS’ in section 2. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? Xermelo in combination with a somatostatin analogs (SSA) is used to treat adults who have diarrhea associated with a condition called carcinoid syndrome, when their diarrhea is not sufficiently well controlled with somatostatin analog treatment. THERAPEUTIC GROUP: substances that affect the digestive system and metabolism. This medicine is used to treat adults with a condition called carcinoid syndrome. In this condition, a tumor, called a ‘neuroendocrine tumor’, releases a substance called serotonin into your bloodstream. When the tumor releases too much serotonin into your bloodstream you can get diarrhea. This medicine works by reducing the amount of serotonin made by the tumor, and this reduces the diarrhea you have. Your doctor will prescribe this medicine if your diarrhea is not sufficiently well controlled with injections of other medicines called ‘somatostatin analogs’ (lanreotide or octreotide). You must keep having injections of these other medicines when taking Xermelo. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • You are sensitive (allergic) to the active ingredient (telotristat ethyl) or to any of the other ingredient Leggi il documento completo
Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Xermelo ® 250 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains telotristat etiprate equivalent to 250 mg telotristat ethyl. Excipient with known effect Each tablet contains 168 mg of lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White to off-white film-coated oval tablets with ‘T-E’ debossed on one side and ‘250’ debossed on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 250 mg three times daily (tid). Available data suggest that clinical response is usually achieved within 12 weeks of treatment. It is recommended to reassess the benefit of continued therapy in a patient not responding within this time period. Based on the high inter-subject variability observed, accumulation in a subset of patients with carcinoid syndrome cannot be excluded. Therefore, intake of higher doses is not recommended (see section 5.2). _Missed doses _ In the event of a missed dose, patients should take their subsequent dose at the next scheduled time point. Patients should not take a double dose to make up for a missed dose. _Special population _ _ _ _Elderly patients _ Page 2 of 13 No specific dose recommendations are available for elderly patients (see section 5.2). _ _ _Renal impairment _ No specific study has been performed in patients with renal impairment. Patients with mild or moderate renal impairment should be treated with caution. No specific dose recommendations are available for patients with mild or moderate renal impairment. The use of Xermelo is not recommended in patients with severe renal impairment and in patients with end-stage renal disease requiring dialysis (see section 5. Leggi il documento completo